Koichi Ichimura

List of Publications by Year
in descending order

113	8,024	94433 37	53230 85
papers	citations	h-index	g-index

117	117	117	10498
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
2	Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas. Cancer Research, 2008, 68, 8673-8677.	0.9	786
3	IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology, 2009, 11, 341-347.	1.2	504
4	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica, 2013, 126, 267-276.	7.7	315
5	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
6	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
7	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	5.2	189
8	An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. Journal of Neuroscience Methods, 2009, 176, 192-199.	2.5	143
9	Genomic characterization of primary central nervous system lymphoma. Acta Neuropathologica, 2016, 131, 865-875.	7.7	138
10	A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Human Molecular Genetics, 2002, 11, 3221-3229.	2.9	129
11	Revisiting <scp>TP</scp>53 Mutations and Immunohistochemistryâ€”A Comparative Study in 157 Diffuse Gliomas. Brain Pathology, 2015, 25, 256-265.	4.1	120
12	A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathologica, 2011, 121, 651-661.	7.7	116
13	Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. , 1998, 22, 9-15.		115
14	Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathology, 2012, 29, 131-139.	1.7	115
15	Molecular pathogenesis of astrocytic tumours. Journal of Neuro-Oncology, 2004, 70, 137-160.	2.9	114
16	High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors. Journal of Neuropathology and Experimental Neurology, 2006, 65, 549-561.	1.7	89
17	Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Scientific Reports, 2018, 8, 11773.	3.3	88
18	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathologica, 2013, 126, 291-301.	7.7	84

#	Article	IF	Citations
19	Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas. Acta Neuropathologica, 2014, 127, 911-925.	7.7	82
20	MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. International Journal of Cancer, 2012, 131, 1104-1113.	5.1	78
21	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	7.7	74
22	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathologica Communications, 2018, 6, 134.	5.2	74
23	Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium. Neuro-Oncology, 2019, 21, 1565-1577.	1.2	74
24	Genomic Analysis of Pilocytic Astrocytomas at 0.97 Mb Resolution Shows an Increasing Tendency Toward Chromosomal Copy Number Change With Age. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1049-1058.	1.7	72
25	Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathologica, 2016, 131, 889-901.	7.7	70
26	Mutational Profile of the PTEN Gene in Primary Human Astrocytic Tumors and Cultivated Xenografts. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1170-1183.	1.7	69
27	IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. International Journal of Oncology, 2012, 41, 1325-1336.	3.3	67
28	Replication Timing of Human Chromosome 6. Cell Cycle, 2005, 4, 172-176.	2.6	66
29	Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL. Brain Pathology, 1998, 8, 263-276.	4.1	65
30	Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathology, 2015, 32, 22-30.	1.7	65
31	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. Acta Neuropathologica, 2017, 133, 445-462.	7.7	64
32	TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathologica, 2013, 126, 939-941.	7.7	62
33	TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathologica, 2021, 142, 323-338.	7.7	58
34	Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathologica, 2011, 121, 753-761.	7.7	46
35	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 789-808.	7.7	45
36	Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Scientific Reports, 2019, 9, 20311.	3.3	45

#	Article	IF	Citations
37	Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clinical Cancer Research, 2003, 9, 4151-8.	7.0	45
38	IDH1/2 mutation detection in gliomas. Brain Tumor Pathology, 2015, 32, 79-89.	1.7	44
39	Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Science, 2019, 110, 2247-2257.	3.9	42
40	Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathologica, 2017, 134, 941-956.	7.7	40
41	Signal transduction pathways and resistance to targeted therapies in glioma. Seminars in Cancer Biology, 2019, 58, 118-129.	9.6	40
42	Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: Possible localization of a neurofibromatosis type 2 modifier gene?. , 1999, 25, 184-190.		37
43	Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Modern Pathology, 2019, 32, 1751-1761.	5.5	35
44	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
45	Molecular markers in pediatric neuro-oncology. Neuro-Oncology, 2012, 14, iv90-iv99.	1.2	30
46	Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Acta Neuropathologica Communications, 2014, 2, 68.	5.2	29
47	TERT promoter hotspot mutations in breast cancer. Breast Cancer, 2018, 25, 292-296.	2.9	29
48	Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers, 2021, 13, 1415.	3.7	28
49	TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathologica Communications, 2020, 8, 201.	5.2	27
50	Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors. Journal of Neuro-Oncology, 2015, 124, 23-32.	2.9	26
51	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
52	Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Modern Pathology, 2021, 34, 688-700.	5.5	25
53	So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?. Neuro-Oncology, 2021, 23, 295-303.	1.2	24
54	Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathology, 2018, 35, 148-158.	1.7	22

#	Article	IF	Citations
55	Presacral malignant teratoid neoplasm in association with pathogenic DICER1 variation. Modern Pathology, 2019, 32, 1744-1750.	5.5	22
56	Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts. Journal of Neurosurgery, 2021, 134, 446-456.	1.6	21
57	Chromosome 7 Rearrangements in Glioblastomas; Loci Adjacent to EGFR Are Independently Amplified. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1138-1145.	1.7	20
58	A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. Neuropathology, 2013, 33, 576-581.	1.2	20
59	IDHâ€mutated astrocytomas with 19qâ€loss constitute a subgroup that confers better prognosis. Cancer Science, 2018, 109, 2327-2335.	3.9	20
60	Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma agedâ€‰â‰¥â€‰75â€‰years. Radiation Oncology, 2019, 14, 200.	2.7	19
61	Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. Acta Neuropathologica, 2017, 133, 321-324.	7.7	18
62	Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. Biochemical and Biophysical Research Communications, 2018, 495, 1292-1299.	2.1	18
63	High-grade glioneuronal tumor with an ARHGEF2â€“NTRK1 fusion gene. Brain Tumor Pathology, 2019, 36, 121-128.	1.7	18
64	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	7.0	17
65	Ependymomaâ€like tumor with mesenchymal differentiation harboring C11orf95â€NCOA1/2 or â€RELA fusion: A hitherto unclassified tumor related to ependymoma. Brain Pathology, 2021, 31, e12943.	4.1	16
66	Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Science, 2021, 112, 4702-4710.	3.9	16
67	12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. Neuro-Oncology, 2022, 24, 834-846.	1.2	16
68	The Complexity of the 7p12 Amplicon in Human Astrocytic Gliomas: Detailed Mapping of 246 Tumors. Journal of Neuropathology and Experimental Neurology, 2000, 59, 1087-1093.	1.7	15
69	Glioblastomas withIDH1/2mutations have a short clinical history and have a favorable clinical outcome. Japanese Journal of Clinical Oncology, 2016, 46, 31-39.	1.3	15
70	Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. BioMed Research International, 2018, 2018, 1-12.	1.9	15
71	Protein Phosphatasesâ€”A Touchy Enemy in the Battle Against Glioblastomas: A Review. Cancers, 2019, 11, 241.	3.7	15
72	Identification of novel SSX1 fusions in synovial sarcoma. Modern Pathology, 2022, 35, 228-239.	5.5	15

#	Article	IF	Citations
73	Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Cancer Science, 2021, 112, 4736-4747.	3.9	15
74	Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. Cancer Science, 2018, 109, 2275-2285.	3.9	14
75	C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta Neuropathologica Communications, 2021, 9, 36.	5.2	14
76	Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. Neuro-Oncology, 2022, 24, 1246-1258.	1.2	14
77	Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome. Brain Tumor Pathology, 2019, 36, 92-101.	1.7	11
78	Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features. Brain Tumor Pathology, 2021, 38, 64-70.	1.7	11
79	Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals. Cancers, 2021, 13, 3611.	3.7	11
80	A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations. Brain Tumor Pathology, 2019, 36, 162-168.	1.7	10
81	Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation. Cancers, 2020, 12, 3641.	3.7	10
82	A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. Biomolecules, 2021, 11, 565.	4.0	10
83	Co-expression of ERG and CD31 in a subset of CIC-rearranged sarcoma: a potential diagnostic pitfall. Modern Pathology, 2022, 35, 1439-1448.	5.5	10
84	Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosomes and Cancer, 2009, 48, 121-131.	2.8	9
85	Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Brain Tumor Pathology, 2012, 29, 183-191.	1.7	9
86	Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort. Cancers, 2022, 14, 979.	3.7	9
87	Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes. Acta Neuropathologica Communications, 2020, 8, 203.	5.2	8
88	The ALK inhibitors, alectinib and ceritinib, induce ALKâ€independent and STAT3â€dependent glioblastoma cell death. Cancer Science, 2021, 112, 2442-2453.	3.9	8
89	Low tumor cell content predicts favorable prognosis in germinoma patients. Neuro-Oncology Advances, 2021, 3, vdab110.	0.7	8
90	Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR. Brain Tumor Pathology, 2020, 37, 154-158.	1.7	7

#	Article	IF	Citations
91	Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathology, 2022, 39, 121-129.	1.7	7
92	Intracranial germinomas in a father and his son. Child's Nervous System, 2014, 30, 2143-2146.	1.1	6
93	Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death. Neurologia Medico-Chirurgica, 2018, 58, 296-302.	2.2	6
94	TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro-Oncology, 2019, 21, 417-418.	1.2	6
95	Histological and genetic analysis of anaplastic pleomorphic xanthoastrocytoma suspected of malignant progression over a 12â€year clinical course. Pathology International, 2019, 69, 608-613.	1.3	5
96	Genomeâ€wide <scp>DNA</scp> methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma. Cancer Science, 2019, 110, 828-832.	3.9	5
97	MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. Journal of Neuro-Oncology, 2022, 157, 561-571.	2.9	5
98	Diffusely infiltrating glioma with CREBBPâ€“BCORL1 fusion showing overexpression of not only BCORL1 but BCOR: A case report. Brain Tumor Pathology, 2022, 39, 171-178.	1.7	5
99	Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis. Histopathology, 2019, 74, 350-354.	2.9	4
100	Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma. Cancer Science, 2021, 113, 697.	3.9	4
101	The clinical characteristics and outcomes of incidentally discovered glioblastoma. Journal of Neuro-Oncology, 2022, 156, 551-557.	2.9	4
102	IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology. Journal of Neuropathology and Experimental Neurology, 2021, 80, 247-253.	1.7	3
103	Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment**. Japanese Journal of Clinical Oncology, 2021, 51, 1028-1035.	1.3	3
104	Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. Journal of Neuro-Oncology, 2021, 154, 121-130.	2.9	3
105	Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. Neurology, 2021, 97, e2114-e2123.	1.1	3
106	Softâ€tissue sarcoma with <scp>MN1â€BEND2</scp> fusion: A case report and comparison with astroblastoma. Genes Chromosomes and Cancer, 2022, 61, 427-431.	2.8	3
107	Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. Cancers, 2022, 14, 2454.	3.7	3
108	MGMT testing always worth an emotion. Neuro-Oncology, 2021, 23, 1417-1418.	1.2	2

#	Article	IF	Citations
109	How to understand the Results of Basic Glioma Genome Sequence Data. Japanese Journal of Neurosurgery, 2017, 26, 806-816.	0.0	2
110	Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma. Radiation Oncology, 2022, 17, 85.	2.7	2
111	Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion. Neuro-Oncology Advances, 0, , .	0.7	2
112	Molecular analyses of rosette-forming glioneuronal tumor of the midbrain tegmentum: A report of two cases and a review of the FGFR1 status in unusual tumor locations. , 0, 13, 213.		1
113	Molecular Diagnosis in WHO Classification of Tumours of the Central Nervous System 2016 : A Domestic Survey and Perspectives. Japanese Journal of Neurosurgery, 2019, 28, 674-685.	0.0	0